
| Pair Name | Baicalin, Doxorubicin | ||
| Phytochemical Name | Baicalin (PubChem CID: 64982 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Baicalin, Doxorubicin | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAD | hsa572 |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
| Result | This study demonstrate that the effect of baicalin on Dox treatment could enhance cytotoxicity toward breast cancer cells via the ROS/[Ca2+]i-mediated intrinsic apoptosis pathway-thus potentially lessening the required dosage of doxorubicin, and further exploring associated mechanisms in combined treatments for breast cancer clinical interventions in the future. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Baicalin Enhances Chemosensitivity to Doxorubicin in Breast Cancer Cells via Upregulation of Oxidative Stress-Mediated Mitochondria-Dependent Apoptosis. Antioxidants (Basel). 2021;10(10):1506. Published 2021 Sep 23. doi:10.3390/antiox10101506 | Click |